The gallbladder cancer market has shown significant growth in the recent past owing to the growing incidence of gallbladder cancer worldwide. The gallbladder is a small pear-shaped organ located below the liver that stores and concentrates bile produced by the liver. Gallbladder cancer, also known as gallbladder carcinoma, occurs due to the uncontrolled growth of malignant (cancerous) cells in the gallbladder. Some of the common symptoms of gallbladder cancer include abdominal pain, lumps in the abdomen, jaundice, nausea, and weight loss.
The global gallbladder cancer market is estimated to be valued at US$ 1,607.47 Mn in 2024 and is expected to exhibit a CAGR of 5.3% over the forecast period 2023 to 2030. Gallbladder cancer treatment options include surgery, chemotherapy, targeted therapy, radiation therapy, and immunotherapy depending on the stage of cancer. Other than treatment, the market also consists of diagnostic products used for detecting gallbladder cancer such as ultrasound, CT scan, MRI, and biopsy.
Key Takeaways
Key players operating in the gallbladder cancer market are Histogen Inc., Cipla Limited, Aclaris Therapeutics, Inc., Merck & Co., Inc., Daiichi-Sankyo Co., Ltd., Johnson and Johnson Services, Inc., Lexington International LLC, Vita-Cos-Med Klett-Loch GmbH, PureTech, Vitabiotics, Dr. Reddy’s Laboratories, HCell Inc., Follica, Inc. and Ranbaxy Laboratories Ltd. The demand for gallbladder cancer treatment has been increasing owing to the rising incidence of gallbladder cancer worldwide. Technological advancements in diagnostic imaging modalities and targeted therapies have improved gallbladder cancer diagnosis and treatment.
Market Trends
Early diagnosis of gallbladder cancer is one of the key trends witnessed in the market. Availability of advanced imaging modalities like CT scans and MRI enable early detection of gallbladder cancer, even at an early stage. This increases survival rates and treatment outcomes. Another major trend is the development of novel targeted therapies. Companies are focusing on developing targeted drugs that can inhibit specific pathways involved in gallbladder cancer growth and progression.
Market Opportunities
High incidence rates in developing countries present lucrative opportunities. According to the WHO, around 84,000 new cases of gallbladder cancer are diagnosed every year globally, with the highest incidence rates in India, Chile and Pakistan. Development of combination therapies focusing on multi-target inhibition is also an emerging opportunity. Using a combination of targeted drugs along with traditional therapies can improve treatment efficacy. Affordable diagnostic devices for resource-limited regions also present growth opportunities.
Impact of COVID-19 on Gallbladder Cancer Market Growth
The COVID-19 pandemic has significantly impacted the growth of the gallbladder cancer market. During the initial lockdown phases imposed by various governments worldwide, many non-essential medical procedures and visits were postponed or cancelled. This led to a decline in the diagnosis of new gallbladder cancer cases as people avoided hospitals and facilities due to fear of contracting the virus. Moreover, resources from the healthcare sector were reallocated to manage the rising number of coronavirus patients requiring critical care. This diversion of focus away from cancer treatment negatively impacted the growth of the gallbladder cancer market in the short term.
However, as restrictions eased in various parts of the world with the flattening of the pandemic curve, the focus once again shifted toward cancer diagnosis and management. Telehealth and teleconsultation also emerged as important tools to continue care delivery while minimizing risks of viral transmission. Researchers accelerated efforts to develop new drugs and treatment avenues for gallbladder cancer in light of the learnings from COVID-19 about drug repurposing, host-pathogen interactions and immunotherapy approaches. Countries also invested more funds into oncology research to address the backlog created due to the pandemic disruptions. All of these measures are expected to support robust growth in the gallbladder cancer market in the long run.
Regions where Gallbladder Cancer Market Value is Concentrated
The gallbladder cancer market in terms of value is highly concentrated in regions with high disease prevalence and advanced healthcare infrastructure to effectively manage the condition. North America represents the largest market for gallbladder cancer treatment globally owing to factors such as the developed research landscape, rising healthcare spending per capita and presence of key market players. Within the region, United States holds the major share assisted by the large patient pool and availability of favorable reimbursement policies. Europe is the second largest market driven by growing government support for cancer control in countries like Germany, United Kingdom and France. Asia Pacific is also emerging as a high growth territory due to rising incomes, expanding insurance coverage and increasing awareness about early detection of gallbladder cancer.
Fastest Growing Region for Gallbladder Cancer Market
The Asia Pacific region is poised to witness the fastest growth in the gallbladder cancer market over the forecast period from 2023 to 2030. This can be attributed to significant improvement in the healthcare infrastructure across developing APAC nations like India, China, South Korea and Indonesia. Alongside economic expansion, these countries are implementing universal healthcare programs and health insurance schemes to boost access to advanced cancer treatments. Furthermore, the increasing burden of non-communicable diseases coupled with growing focus on contract research and manufacturing is inviting more investments in oncology drug development in Asia Pacific. The Asia Pacific gallbladder cancer market is also driven by rising affordability of care, expanding medical tourism industry and improving awareness about gallbladder cancer symptoms and risk factors in the region.
Priya Pandey is a dynamic and passionate editor with over three years of expertise in content editing and proofreading. Holding a bachelor's degree in biotechnology, Priya has a knack for making the content engaging. Her diverse portfolio includes editing documents across different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. Priya's meticulous attention to detail and commitment to excellence make her an invaluable asset in the world of content creation and refinement.
(LinkedIn- https://www.linkedin.com/in/priya-pandey-8417a8173/)
